NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
42 trialsNCT05327010 2026-03-18
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05554341 2026-03-18
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554380 2026-03-18
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05638295 2026-03-17
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04927416 2026-03-13
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06311214 2026-03-06
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03872427 2025-11-14
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03284385 2025-10-27
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00019695 2024-03-04
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00019760 2023-10-31
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03394027 2022-08-23
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001880 2021-11-10
Stem Cell Transplantation for Metastatic Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00670748 2019-11-19
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01095523 2017-07-02
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00019604 2017-02-03
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00550654 2017-01-13
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02062359 2016-06-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00390468 2014-05-28
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT00408551 2013-12-19
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00436267 2013-12-19
Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003878 2013-06-21
Carmustine Implants in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103298 2013-06-20
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00301847 2013-02-11
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
National Cancer Institute (NCI)
Phase 2 Completed
NCT00001832 2012-12-21
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00089401 2012-05-14
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00019786 2012-03-23
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00438737 2011-09-02
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00393029 2011-08-15
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00544349 2011-05-17
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00875355 2009-08-26
Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00001165 2008-03-04
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001193 2008-03-04
A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001250 2008-03-04
Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001493 2008-03-04
Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001685 2008-03-04
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001705 2008-03-04
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
National Institutes of Health Clinical Center (CC)
Phase 2 Completed